BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.

Phase 1

Completed

Conditions: Clinical Pharmacology

Interventions: Drug: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil

First Posted Date: 2017-05-02

Last Posted Date: 2017-05-02

Lead Sponsor: Bayer

Target Recruit Count: 12

Registration Number: NCT03136666

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaferon, BAY86-5046)
Device: Betaconnect auto-injector
Device: myBETAapp

First Posted Date: 2017-05-01

Last Posted Date: 2019-03-26

Lead Sponsor: Bayer

Target Recruit Count: 96

Registration Number: NCT03134573

Locations: 🇩🇪
Many locations, Multiple Locations, Germany

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BAY1436032

First Posted Date: 2017-04-25

Last Posted Date: 2019-05-14

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT03127735

Locations: 🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇩🇪
Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany
🇩🇪
Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany

and more 10 locations

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure

Phase 2

Completed

Conditions: Diabetic Foot

Interventions: Drug: BAY1193397
Drug: Placebo

First Posted Date: 2017-04-25

Last Posted Date: 2020-08-13

Lead Sponsor: Bayer

Target Recruit Count: 23

Registration Number: NCT03128320

Locations: 🇬🇧
Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom

Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

Not Applicable

Completed

Conditions: Contraception

Interventions: Procedure: Blood draw
Device: ESSURE (BAY1454032)
Procedure: Laparoscopic tubal sterilization

First Posted Date: 2017-04-25

Last Posted Date: 2025-01-08

Lead Sponsor: Bayer

Target Recruit Count: 990

Registration Number: NCT03127722

Locations: 🇺🇸
Columbus OB-GYN/Radiant Research, Columbus, Ohio, United States
🇺🇸
Complete Healthcare for Women, Inc., Columbus, Ohio, United States
🇺🇸
Universal Axon Clinical Research, Miami, Florida, United States

and more 54 locations

Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea

Completed

Conditions: Endometriosis and Dysmenorrhea

Interventions: Drug: BAY86-5300_YAZ-Flex

First Posted Date: 2017-04-24

Last Posted Date: 2022-11-16

Lead Sponsor: Bayer

Target Recruit Count: 715

Registration Number: NCT03126747

Locations: 🇯🇵
Many locations, Multiple Locations, Japan

A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

Completed

Conditions: Menopause

Interventions: Drug: BAY86-4891

First Posted Date: 2017-04-24

Last Posted Date: 2021-06-18

Lead Sponsor: Bayer

Target Recruit Count: 1570

Registration Number: NCT03126773

Locations: 🇷🇺
Many locations, Multiple Locations, Russian Federation

Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116

Phase 1

Terminated

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: BAY1161116
Drug: Placebo
Drug: Itraconazole

First Posted Date: 2017-04-18

Last Posted Date: 2018-05-17

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT03119077

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Use of Direct Oral Anticoagulants in UK

Completed

Conditions: Stroke

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Apixaban
Drug: Dabigatran

First Posted Date: 2017-04-18

Last Posted Date: 2020-04-17

Lead Sponsor: Bayer

Target Recruit Count: 31336

Registration Number: NCT03119116

Locations: 🇬🇧
Many Locations, Multiple Locations, United Kingdom

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Anetumab ravtansine (BAY94-9343)

First Posted Date: 2017-04-05

Last Posted Date: 2022-06-30

Lead Sponsor: Bayer

Target Recruit Count: 173

Registration Number: NCT03102320

Locations: 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
CHU de Liège, Liege, Belgium
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 69 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy